Evidence map›Paper›PMID 38204497›Full record

ArticleThe Lancet regional health. Western Pacific2024

Poliovirus serological assay after the cVDPV1 outbreak in Papua New Guinea: a cross-sectional study from 2020 to 2021.

William Pomat, Rocio Lopez Cavestany, Visalakshi Jeyaseelan, Rebecca Ford, Janet Gare, Tigran Avagyan, Varja Grabovac, Deborah Bettels, Dessie Mekonnen, Kathryn Ann Vetter Jones and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Lancet regional health. Western Pacific, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 4 countries.

William PomatPapua New Guinea Institute of Medical Research, Goroka, Eastern Highlands Province, Papua New Guinea.
Rocio Lopez CavestanyPolio Eradication Department, World Health Organization Headquarters, Geneva, Switzerland.
Visalakshi JeyaseelanPolio Eradication Department, World Health Organization Headquarters, Geneva, Switzerland.
Rebecca FordPapua New Guinea Institute of Medical Research, Goroka, Eastern Highlands Province, Papua New Guinea.
Janet GarePapua New Guinea Institute of Medical Research, Goroka, Eastern Highlands Province, Papua New Guinea.
Tigran AvagyanWorld Health Organization, Western Pacific Regional Office, Manila, Philippines.
Varja GrabovacWorld Health Organization, Western Pacific Regional Office, Manila, Philippines.
Deborah BettelsWorld Health Organization, Papua New Guinea Country Office, Port Moresby, National Capital District, Papua New Guinea.
Dessie MekonnenWorld Health Organization, Papua New Guinea Country Office, Port Moresby, National Capital District, Papua New Guinea.
Kathryn Ann Vetter JonesUS Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Bernardo Alfredo MainouUS Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Ondrej MachPolio Eradication Department, World Health Organization Headquarters, Geneva, Switzerland.
Papua New Guinea Institute of Medical Research · PGWorld Health Organization · CHCenters for Disease Control and Prevention · USWorld Health Organization Regional Office for the Western Pacific · PH

Funding

World Health Organization 001
6 · The paper itself

Abstract

Background: In June 2018, a type 1 circulating vaccine-derived poliovirus (cVDPV1) outbreak was declared in Papua New Guinea (PNG), resulting in a total of 26 paralytic confirmed cases. Eight vaccination campaign rounds with bivalent oral poliovirus vaccine (bOPV) were carried out in response. Prevalence of neutralizing polio antibodies in children was assessed two years after the outbreak response was completed. Methods: We conducted a cross-sectional serological survey among children aged 6 months-10 years selected from six provinces in PNG to evaluate seroprevalence of neutralizing polio antibodies to the three poliovirus serotypes and analyse sociodemographic risk factors. Findings: We included 984 of 1006 enrolled children in the final analysis. The seroprevalence of neutralizing polio antibodies for serotype 1, 2 and 3 was 98.3% (95% CI: 97.4-98.9), 63.1% (95% CI: 60.1-66.1) and 95.0% (95% CI: 93.6-96.3), respectively. Children <1 year had significantly lower type 1 seroprevalence compared to older children (p < 0.001); there were no significant differences in seroprevalence among provinces. Interpretation: PNG successfully interrupted transmission of cVDPV1 with several high coverage bOPV campaigns and seroprevalence remained high after two years. The emergence of cVDPV strains underscores the importance of maintaining high levels of routine immunization coverage and effective surveillance systems for early detection. Funding: World Health Organization through a Rotary International IPPC grant.

Indexed as

Bivalent oral poliovirus vaccineOutbreak responsePapua New GuineaPolioSeroprevalenceVaccine-derived poliovirus

Identifiers

PMID38204497
PMCPMC10777103
OpenAlexW4389987655

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.